Extracellular matrix degradation by metalloproteinases and central nervous system diseases
| Autor: | Anton Lukes, Gary A. Rosenberg, Manuela Lukes, Sheila Mun-Bryce |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Proteases
Proteolysis Neuroscience (miscellaneous) Matrix metalloproteinase Biology Extracellular matrix Cellular and Molecular Neuroscience Fibrosis Central Nervous System Diseases Extracellular medicine Animals Humans Growth Substances medicine.diagnostic_test Metalloendopeptidases Tissue Inhibitor of Metalloproteinases medicine.disease Cell biology Extracellular Matrix Neurology Gliosis Blood-Brain Barrier Immunology medicine.symptom Extracellular Matrix Degradation |
| Zdroj: | Molecular neurobiology. 19(3) |
| ISSN: | 0893-7648 |
| Popis: | Matrix metalloproteinases (MMPs) are a gene family of neutral proteases involved in normal and pathological processes in the central nervous system (CNS). Normally released into the extracellular space, MMPs break down the extracellular matrix (ECM) to allow cell growth and to facilitate remodeling. Proteolysis becomes pathological when the normal balance between the proteases and their inhibitors, tissue inhibitors to metalloproteinases (TIMPs), is lost. Cancer cells secrete neutral proteases to facilitate spread through the ECM. MMPs increase capillary permeability, and they have been implicated in demyelination. Neurological diseases, such as brain tumors, multiple sclerosis, Guillain-Barre, ischemia, Alzheimer's disease, and infections, lead to an increase in the matrix-degrading proteases. Two classes of neutral proteases have been extensively studied, namely the MMPs and the plasminogen activators (PAs), which act in concert to attack the ECM. After proteolytic injury occurs, the process of ECM remodeling begins, which can lead to fibrosis of blood vessels and gliosis. TIMPs are increased after the acute injury and may add to the fibrotic buildup of ECM components. Thus, an imbalance in proteolytic activity either during the acute injury or in recovery may aggravate the underlying disease process. Agents that affect the proteolytic process at any of the regulating sites are potentially useful in therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink